IP Verse

Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating Cancer

Patent No. EP2651442 (titled "Universal Anti-Tag Chimeric Antigen Receptor-Expressing T Cells And Methods Of Treating Cancer") was filed by University OF Maryland on Dec 14, 2011. The application was issued on Apr 22, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
STRAWMANJan 21, 2021POTTER CLARKSON
AVENCELL EUROPEJan 20, 2021KAILUWEIT & UHLEMANN PATENTANWALTE PARTNERSCHAFT MBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2651442

UNIVERSITY OF MARYLAND
Application Number
EP11849221A
Filing Date
Dec 14, 2011
Status
Granted And Under Opposition
Mar 20, 2020
Publication Date
Apr 22, 2020
External Links
Slate, Register , Google Patents